Our services that use liquid biopsies (biofluids, such as serum, plasma, urine and cell culture supernatant) as a starting material offer a minimally invasive approach and provide tools for biomarker discovery and translational research that perform well with low-input nucleic acids.
Liquid biopsy
Liquid biopsy is less invasive than taking tissue samples. The ease of using biofluids, makes these sample types ideal to identify and monitor disease biomarkers more frequently and efficiently than is practical with solid biopsies.
Genomic Services for biofluids
The concentration of miRNAs in biofluids is very low, making their detection and quantification difficult. QIAGEN Genomic Services overcomes these limitations by combining our innovative QIAseq miRNA-seq technology with decades of technical expertise with biofluid samples. Extend your in-house resources with the expertise and high-quality services you can expect from us.
Benefits of our services using miRNA from biofluids:
- End-to-end service: We take care of every step, from sample preparation to data analysis
- qPCR-based quality controls: Locked nucleic acid (LNA) RNA spike-in controls are used to monitor RNA extraction efficiency, miRNA content, inhibition and hemolysis
- Highly efficient library preparation: Optimized protocols are available for biofluids with limited RNA content
- Sequencing quality control: Data is evaluated reproducibility and linearly using a comprehensive set of 52 RNA spike-ins, spanning a wide range of concentrations
- Ready-to-publish data: We deliver comprehensive reports and data packages and provide guidance on the next steps